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ABSTRACT: Inorganic nanoparticle-based biomedical imaging probes have been
studied extensively as a potential alternative to conventional molecular imaging
probes. Not only can they provide better imaging performance but they can also offer
greater versatility of multimodal, stimuli-responsive, and targeted imaging. However,
inorganic nanoparticle-based probes are still far from practical use in clinics due to
safety concerns and less-optimized efficiency. In this context, it would be valuable to
look over the underlying issues. This outlook highlights the recent advances in the
development of inorganic nanoparticle-based probes for MRI, CT, and anti-Stokes
shift-based optical imaging. Various issues and possibilities regarding the construction
of imaging probes are discussed, and future research directions are suggested.
■ INTRODUCTION
Bioimaging refers to the visualization of biological structures
and processes. A variety of techniques with their own
advantages have been developed for that purpose to meet the
needs in various clinical and laboratory settings.1−4 In many
cases, imaging probes that can label target molecules or organs
are used to provide enhanced visibility and to enable the
acquisition of more detailed structural and functional
information.5−7 Consequently, the use of imaging probes is
becoming indispensable for biological research and disease
diagnosis.
Recent advances in the development of imaging probes have
led to the bioimaging at subcellular or molecular level.8−10 That
said, the majority of the imaging probes currently used in clinics
are organic molecules or metal−organic compounds,11−13
whose utility is limited because of their intrinsic physical and
physiological properties. To list a few examples, fluorescent
dyes used for optical imaging suffer from photobleaching,14 and
magnetic resonance imaging (MRI) contrast agents made of
Gd3+-chelates exhibit weak contrast effect due to their low
magnetic moment.15 These small molecule-based probes also
have a short circulation time in vivo, resulting in poor targeting
efficiency and insufficient imaging enhancement.16
Nanotechnology has facilitated the development of un-
precedented imaging probes with outstanding perform-
ance.17−19 Inorganic nanoparticles are one of the most widely
studied materials in this regard due to their unique physical and
chemical properties that originate from their nanoscale
dimensions.20 Various nanoparticle probes for bioimaging
were developed using their magnetic, X-ray attenuation, and
optical properties (Figure 1). For example, magnetic nano-
particles (e.g., superparamagnetic iron oxide nanoparticles)
have been applied as strong T2 MRI contrast agents, showing
much improved detection sensitivity over conventional Gd3+-
based MRI contrast agents.21−23 Nanoparticles of high-Z
elements (e.g., gold,24,25 bismuth,26−28 and tantalum29,30)
have been studied for enhanced computed tomography (CT)
contrast agents owing to their high X-ray attenuation. The
better optical and chemical stability of quantum dots (QDs)
and their relatively easily tunable emission wavelength
compared with those of fluorescent dyes enable the use of
QDs as robust fluorescent tags in optical imaging.31−33 Despite
these advantages, inorganic nanoparticle-based imaging probes
still have many drawbacks that prevent their extensive use in
clinical settings, which include magnetic susceptibility artifacts
of T2 MRI contrast agents,
34 photoinduced tissue damage from
ultraviolet (UV) excitation source for QDs,35 and potential
toxicity of heavy metal-containing nanoparticles.36,37 As a result,
very few nanoparticle probes are approved for clinical use.
Many efforts have been made in recent years to address the
limitations of typical inorganic nanoparticle imaging probes. To
overcome the intrinsic limitations of T2 MRI, extremely small
iron oxide nanoparticles were utilized as T1 MRI contrast
agents.38,39 Shallow tissue penetration depth of UV excitation
could be circumvented by using near-infrared (NIR) light for
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the excitation of nanoparticle probes.40−43 Moreover, several
nanoparticle surface modification methods have been devel-
oped to provide enhanced biocompatibility and functionalities
such as stimuli-responsiveness, targeted imaging, and therapy.44
Here, we focus on the recent progress in inorganic
nanoparticle probes for MRI, CT, and anti-Stokes shift-based
optical imaging, of which the characteristics are summarized in
Table 1. We discuss various issues that need to be considered
when developing nanoparticle probes. Finally, we propose
future research directions for the next generation imaging
probes.
■ MRI CONTRAST AGENTS
MRI is a noninvasive medical imaging technique based on the
principle of nuclear magnetic resonance (NMR).45 In a strong
magnetic field, hydrogen nuclei absorb resonant radiofrequency
pulses, and subsequently the excited nuclei return to the initial
state by emitting the absorbed radio frequency energy. MRI
contrast is generated by the different relaxation characteristics
of the hydrogen atoms in tissues that are affected by the
presence of nearby magnetic materials. For example, para-
magnetic materials enhance the longitudinal relaxation
processes (also called T1 relaxation processes), producing
brighter MR signal, while superparamagnetic and ferromagnetic
materials accelerate the transverse relaxation processes (also
called T2 relaxation processes), resulting in hypointense MR
signal. Using these properties, complexes of paramagnetic
gadolinium ions (Gd3+) and superparamagnetic iron oxide
nanoparticles (SPIONs) have been used as T1 and T2 contrast
agents, respectively.46 Recently, though, most nanoparticle-
based MRI contrast agents have been withdrawn from the
market, leaving Gd(III) complexes to dominate the current
market for the MRI contrast agents.47
This situation brings up a question: is it still worth pursuing
nanoparticle-based MRI contrast agents? To deal with this
question, it is necessary to consider various factors including
safety, efficacy, and market shares. First-generation magnetic
nanoparticle-based T2 MRI contrast agents such as Feridex and
Resovist were used to detect liver lesions, and second-
generation agents such as Combidex were developed for the
diagnosis of lymph metastases.34 They were withdrawn from
the market not for safety concerns, but rather due to their small
market shares: T1 contrast agents are preferred in clinics due to
bright MR images, and more importantly, Gd(III)-based T1
contrast agents are able to cover most organs including the
liver.48 Furthermore, the contrast effects of the early generation
magnetic nanoparticle-based contrast agents were not suffi-
ciently strong owing to their small core size and low
crystallinity.49
Newly developed magnetic nanoparticles have a strong
chance to compete with the Gd(III)-based contrast agents.17
Figure 1. Current status of inorganic nanoparticle-based bioimaging and future direction.
Nanotechnology has facilitated
the development of unprece-
dented imaging probes with out-
standing performance.
Table 1. Characteristics of Various Nanoparticle-Based Imaging Modalities







magnetic resonance imaging (MRI) para-/superpara-/ferromagnetic nanoparticles (Gd, Fe, Mn,
etc.)
∼100 μm μM−mM no limit
computed tomography (CT) nanoparticles of high-Z elements (Ba, I, Au, Ta, etc.) ∼100 μm ∼1 mM no limit
anti-Stokes shift-based optical
imaging
doped quantum dots, upconverting nanoparticles <1 μm <1 μM <1 mm
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First, while a serious side effect of Gd(III) complexes, such as
nephrogenic systemic fibrosis, is an issue of major concern,50
iron oxides are generally regarded as benign and biologically
tolerable.51 When intravenously injected, the iron oxide
nanoparticles are typically degraded in liver and spleen, and
subsequently incorporated into iron metabolic pathways.52
Indeed, although the early generation SPION-based contrast
agents for intravenous injection are no longer available in
clinics, iron oxide nanoparticles are still used for the treatment
of iron deficiency anemia53 and for MRI of gastrointestinal tract
via oral administration.54
Second, nanoparticle syntheses based on the thermal
decomposition of metal complexes yield high-quality nano-
particles with tunable size and superior crystallinity.23,55 As a
result, the magnetic property of the nanoparticles can be
controlled from nearly paramagnetic to ferromagnetic by tuning
their size from a few to ∼100 nm (Figure 2a,b). Such
modulation of nanoparticle size allows the magnetic nano-
particles to be used either as a nontoxic alternative to Gd(III)-
based T1 contrast agents or as a highly sensitive T2 contrast
agent. For example, extremely small-sized iron oxide nano-
particles (ESIONs) less than 3 nm in core size exhibit a large T1
contrast effect in high-resolution MR angiography.38 On the
other hand, ferrimagnetic iron oxide nanoparticles (FIONs)
with a diameter larger than 30 nm enable highly sensitive T2-
weighted MRI of individual cells due to their strong magnetic
property and facile cellular uptake.56 In addition, FIONs with
an average core size of 22 nm exhibit ∼7 times stronger T2
contrast effects than those of the first generation SPION-based
agents predicted by outer-sphere relaxation theory.21 Such a
strong contrast effect can be attributed to the balance between
the magnetization and the diffusion rate of the 22 nm-sized
FIONs, which respectively are directly and inversely propor-
tional to the nanoparticle size.57 Moreover, it is also possible to
control the MR contrast effect by changing the magnetic
composition of nanoparticles. For instance, the addition of
paramagnetic Gd3+ ions into iron oxide nanoparticles improves
T1 contrast effect due to the increased interactions between the
Gd3+ ions and water molecules.58 Likewise, manganese ferrite
and zinc-doped ferrite nanoparticles show increased net
magnetization, resulting in much stronger T2 contrast
effect.22,59
Third, while modification of Gd(III) complexes usually
requires complicated multistep organic reactions, the surface of
nanoparticles can be modified relatively easily using conven-
tional bioconjugate chemistry with various functional mole-
cules.60 Since the interactions between biological tissues and
nanoparticles are mainly determined by the surface character-
istics of the nanoparticles, biodistribution and cellular uptake of
the nanoparticles can be readily controlled by the surface
modification.44 Furthermore, conjugation of targeting ligands
allows more accurate diagnosis by providing information on the
biological processes of interest.61 To date, various targeting
ligands including antibodies,62 aptamers,63 folic acid,64 and Arg-
Gly-Asp (RGD) peptide65 have been studied for tumor
Figure 2. (a) Field-dependent magnetization (M−H) curves at 300 K for iron oxide nanoparticles of various sizes (left). Description of the spin
canting effect in the iron oxide nanoparticles of various sizes (right). (b) In vivo MR images of the xenografted tumor before (left) and after (right)
intravenous administration of FIONs. (c) Artifact filtering imaging agent (mAFIA) that comprises a combination of paramagnetic Gd-MOF and
superparamagnetic nanoparticles for T1−T2 dual-mode MRI. (d) Tumor pH-responsive magnetic nanogrenades composed of self-assembled
extremely small-sized iron oxide nanoparticles and pH-sensitive ligands. Reprinted with permission from refs 21, 38, 67, and 74. Copyright 2011,
2012, and 2014 American Chemical Society.
This situation brings up a ques-
tion: is it still worth pursuing
nanoparticle-based MRI contrast
agents? To deal with this ques-
tion, it is necessary to consider
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diagnosis, leading to more enhanced binding affinity and
specificity. In addition to the targeting ligands, various
functional molecules such as fluorescence dyes, radioisotopes,
and drugs can also be attached to the nanoparticles, which
allows multimodal imaging or simultaneous imaging and
therapy (referred to as theragnosis).66
As described above, there is still enormous potential in the
nanoparticle-based MRI contrast agents, and new trials for
more sensitive MR imaging are in progress. One of the
challenging issues in the development of MR contrast agents
lies in overcoming the intrinsic limitations of MRI such as low
sensitivity and artifact signals. For example, either hyperintense
or hypointense signal can be generated from endogenous
factors such as fat, air, bleeding, calcification, or metal
deposition, and they are sometimes confused with MR signals
generated by contrast agents.34 To address this issue, T1−T2
dual-mode MRI contrast agents have been introduced by
combining superparamagnetic nanoparticles with paramagnetic
metal ions (Figure 2c).67 The dual-mode contrast agents
generate bright and dark signals in T1- and T2-weighted MRI,
respectively, enabling the intrinsic ambiguities to be overcome.
In addition, sensitivity and accuracy of MRI can be improved by
obtaining complementary information using multimodal
imaging.68 Therefore, various methods of preparing multimodal
imaging probes have been proposed, including the direct
conjugation of fluorescent molecules or radioisotopes,69 the
assembly of magnetic nanoparticles with quantum dots (QDs)
or upconversion nanoparticles (UCNPs),70 and the doping of
radioisotopes into magnetic nanoparticles.71
Another challenging issue is designing the way that MR
contrast agents respond to the stimuli of surrounding
environments such as pH, temperature, and specific enzymes.
For the case of Gd(III)-complex MR contrast agents,
conformational changes of their chelate structures in response
to various stimuli have been proposed.72 In contrast, there have
been scarce reports on the stimuli-responsive nanoparticle-
based MR contrast agents because a magnetic field generated
by superparamagnetic nanoparticles is not affected by
conformational change of ligands, making the contrast effect
“always on”. On the other hand, clustering of the magnetic
nanoparticles can change the T2 relaxation rate, which is
referred to as magnetic relaxation switch (MRS).73 Because the
aggregation of nanoparticles can be induced by specific
interactions with specific target molecules, various small
molecules including oligonucleotides, enzymes, and drugs are
detected by MRS using MRI scanners and NMR spectrom-
eters.61 However, in vivo MRS remains very challenging as
signal attenuation depends on the nanoparticle concentration as
well as the degree of clustering. Recently, it is shown that
extremely small iron oxide nanoparticles assembled within pH-
responsive polymers can activate the MR signals in acidic
conditions (Figure 2d).74 When the nanoparticles are
aggregated, strong T2 contrast effect prevents T1 contrast
effect. However, the disassembly of the nanoparticles in acidic
condition leads to increase in r1 and decrease in r2, which
results in signal enhancement in T1-weighted MRI.
Although magnetic nanoparticles are not currently available
as MR contrast agents for systemic delivery, much attention
and effort has been made to develop superior nanoparticle-
Figure 3. (a) X-ray attenuation factors of various elements. (b) Simulated attenuations of I, Yb, Ta, and Au against X-ray produced at 80 kVp (A),
100 kVp (B), 120 kVp (C), and 140 kVp (D). (c) Schematic illustration of RITC-doped tantalum oxide nanoparticles for multimodal imaging. (d) In
vivo CT images (left) and optical images (right) of the sentinel lymph node of the rat 2 h after intradermal injection of RITC-doped tantalum oxide
nanoparticles in both paws. Reprinted with permission from refs 29 and 82. Copyright 2011 American Chemical Society and 2015 RSNA.
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based contrast agents that hold great promise to provide
enhanced sensitivity and more accurate diagnosis. Besides MR
contrast agents based on iron oxide nanoparticles, lanthanide
ion-doped nanoparticles are also strong candidates for novel
MRI contrast agents. For example, NaGdF4 nanoparticles have
been developed as multimodal imaging agents for T1-weighted
MRI, CT, and upconversion imaging.75 In addition, Dy3+ and
Ho3+ ions exhibit unique magnetic characteristics such as short
electronic relaxation time and large magnetic moment, which
are suitable for high-field MRI.76 Although high-field MRI
improves the resolution and sensitivity, the contrast effect of
iron oxide nanoparticles is marginally increased because their
magnetization is already saturated. On the other hand, the
magnetization of Dy3+ and Ho3+ is not saturated at the high
magnetic field, making NaHoF4 and NaDyF4 good candidates
for a T2 contrast agent for high-field MRI. Furthermore, it is
expected that optimized contrast effect can be obtained by
modulating particle size, surface coating, and magnetic field.
■ CT CONTRAST AGENTS
Computed tomography (CT) is a medical imaging procedure
based on the interaction of X-ray with a body or a contrast
agent.18 While rotating an X-ray tube and a detector, the
intensity of X-ray is measured from different angles, and cross-
sectional (tomographic) images are generated with the aid of a
computer using the X-ray intensity profiles. CT is one of the
most widely used whole body imaging techniques owing to its
high spatial resolution and rapid image acquisition. As such, it is
frequently employed to visualize various anatomical structures,
including brain, lung, cardiovascular system, and abdominal
diseases. The innate sensitivity of CT is not sufficiently high for
most applications, and thus contrast agents are often required
to detect a subtle change of soft tissues. Approximately half of
the CT scans in clinics are aided by contrast agents.77
Since the X-ray attenuation effect of a material generally
increases with its atomic number, high-Z elements are preferred
as CT contrast agents.78 To date, barium- and iodine-based
contrast agents have been used in clinical situations. Because
CT can detect approximately 10−2 M concentration of a
contrast agent,79 a high dose should be administered, which
raises a concern about the toxicity of the contrast agents. For
example, although barium sulfate suspension has been
administered via oral route for gastrointestinal imaging for
decades, it cannot be used as an intravascular contrast agent
due to its renal and cardiovascular toxicity.80 Iodine-based small
molecules such as iopamidol and iodixanol were approved as
intravenous CT contrast agents by the Food and Drug
Administration of the United States. There are still several
concerns regarding the safety of the iodinated contrast agents
such as allergic reaction and renal toxicity.81 In addition, the
blood circulation time of the iodinated contrast agents is very
short, preventing their preferential accumulation in a lesion.
Besides toxicity and pharmacokinetics, barium- and iodine-
based CT contrast agents do not exhibit sufficient CT contrast
effect at higher X-ray tube voltages.82 This is because the X-ray
attenuation effect of an element sharply increases at its K-edge
energy level, and subsequently decreases at higher energy levels
(Figure 3a).83 Many of the current CT scanners are operated at
tube voltages ranging from 80 to 140 kV, and high voltages are
usually used for large or obese patients. Given that the K-edge
energy levels of iodine and barium are 33.2 and 37.4 keV,83
respectively, there is a large mismatch between the energy
required for the peak attenuation and the average energy of X-
ray photons emitted from the high voltage tubes. For elements
that have too high K-edge energy levels such as gold (80.7 keV)
or bismuth (90.5 keV), their contrast effects are not very strong
either, because the majority of the emitted X-ray photons
generated by current tubes have lower energy than the K-edge
levels of those elements.82 It is noteworthy that polychromatic
X-ray is generated in an X-ray tube, and the tube voltage
represents the maximum energy of the generated X-ray
photons. Therefore, the contrast effect of an element should
be evaluated in a wide range of X-ray energies rather than by an
attenuation coefficient at a single energy level (Figure 3b).
Recent reports show that materials with intermediate K-edge
levels such as ytterbium (K-edge at 61.3 keV) and tantalum (K-
edge at 67.4 keV) exhibit higher CT contrast effect compared
with iodine.82
Last but not least, the market price of the CT contrast agents
is also a critical factor for the regular use of CT in clinics
because a large amount of dose is typically required for each
scanning session. For example, although the gold-based CT
contrast agents are attractive as an alternative to iodinated
contrast agents owing to their good biocompatibility and facile
synthesis,24,25 roughly 50 g of gold is consumed for each whole
body scanning session, which makes the clinical use of gold-
based CT contrast agents almost unrealistic in terms of cost.
Lanthanides such as ytterbium can be cheaper alternatives, but
the industrial production scale of lanthanides is not large
enough to provide a sufficient amount of CT contrast agents.84
Although the radiation dose of CT is a great concern,85 this
does not lower the importance of the contrast agents. By virtue
of its fast scan speed, wide availability, and low cost, CT is still
the most popular imaging tool. Various CT scanning methods
and image reconstruction techniques have been actively
developed to overcome current limitations.86−88 Since contrast
agents allow higher conspicuity of images, it is anticipated that
optimized contrast agents will reduce both the radiation
exposure and the administered dose, leading to safer imaging.
In conjunction with novel imaging techniques, the optimized
contrast agents also would enable new diagnostic capabilities of
CT by providing molecular and cellular information in addition
to simple anatomical details.9 For example, nanoparticles of
high-Z elements have been used for imaging of blood vessels,25
tumors,27 transplanted cells,89 and atherosclerosis.88 Further-
more, development of lanthanide-based imaging75 (e.g.,
upconversion optical imaging and T1-weighted MRI) and
conjugation of fluorescence dyes allow multimodal imaging
(Figure 3c).29 These multifunctional nanoparticles are expected
to lead to more accurate diagnosis and facile treatment by
combination image-guided procedures (Figure 3d). Unlike
other imaging modalities, CT imaging typically requires a large
amount of contrast agents owing to its low sensitivity, which
may cause serious side effects. Although most reports on CT
contrast agent based on high-Z elements have stated that the
nanoparticles are safe, their long-term toxicity has yet to be
elucidated. For successful translation into clinical use, it is
Besides MR contrast agents based
on iron oxide nanoparticles, lan-
thanide ion-doped nanoparticles
are also strong candidates for
novel MRI contrast agents.
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desirable to develop the optimized nanoparticles with favorable
biodistribution profile, while maintaining rapid excretion.
■ MULTIPHOTON FLUORESCENCE IMAGING
PROBES
While whole-body imaging techniques such as MRI and CT
play an important role in medical imaging owing to their high
resolution and superior penetration depth, their long
acquisition time prevents their practical use in real-time
monitoring. Fluorescence imaging can be used to overcome
such limitations. In general, fluorescence imaging is capable of
obtaining high temporal and spatial resolution with good
sensitivity.90,91 The utility of in vivo fluorescence imaging for
live animals, however, has been hampered by the shallow
penetration depth of light in tissues and decreased spatial
resolution that comes from light scattering. For this reason,
there have been demands for the development of innovative
fluorescence imaging probes and techniques. One of the recent
examples of progress in this field is utilizing the anti-Stokes
emission process that generates emission light with a shorter
wavelength than that of the excitation light.92,93 If combined
with near-infrared (NIR) excitation sources, increased tissue
penetration depth, as well as reduced background autofluor-
escence or light scattering, can be achieved.94
Multiphoton absorption is a well-known anti-Stokes emission
process that has a potential to reduce both the photoinduced
damage of samples and photobleaching of fluorophores.92
Unfortunately, most small molecule-based multiphoton fluo-
rescent dyes still suffer from their low photostability that
prevents repeated excitation and prolonged imaging. Therefore,
inorganic nanoparticle-based multiphoton fluorescence probes
are studied as an alternative due to their improved resistance to
photobleaching and relatively facile surface modification with
functional molecules. Especially, semiconducting QDs are very
attractive in that their emission spectra are tunable and their
multiphoton absorption cross sections are much larger than
those of traditional fluorescent dyes.95 There are several other
issues that need to be considered to fully make use of the
potential of the QD-based multiphoton fluorescence probes in
bioimaging, most notably safety and imaging efficiency.
While cadmium-containing QDs such as CdSe/CdS/ZnS
core−shell nanoparticles have been demonstrated as a two-
photon imaging probe, potential toxicity from cadmium is a
major concern. To address this issue, cadmium-free QDs have
been studied.96−98 For example, manganese-doped ZnS
(ZnS:Mn) nanoparticles have been used in multiphoton
imaging.97 Besides their low toxicity, the manganese dopants
change the emission wavelength from ∼430 nm to ∼580 nm,
allowing more light to escape from the tissues. The large three-
photon absorption cross section of ZnS:Mn nanoparticles,
which is 4 orders of magnitude larger than those of ultraviolet
(UV) fluorescent dyes, enables the three-photon excitation by
920 nm NIR laser, allowing deeper tissue penetration compared
with two-photon imaging (Figure 4a). Spatial resolution is also
much improved due to the reduced out-of-focus excitation and
diminished background fluorescence (Figure 4b). Other than
the ZnS:Mn nanoparticles, InP/ZnS99 or CuInS2/ZnS QDs
100
are also promising candidates for less-toxic probes.
Figure 4. (a) Energy diagram of ZnS:Mn nanoparticles excited by multiphoton absorption. Two-photon absorption of ZnS (600 nm) or Mn2+ (NIR-
II region) induces orange emission. Three-photon absorption of ZnS also induces orange emission. (b) Two-photon image of FITC and three-
photon image of ZnS:Mn nanoparticles. Three-photon imaging showed better spatial resolution. (c) Transmission spectra of tumor tissue and blood.
The NIR-II region exhibits improved transmission. (d) PL intensity of ZnS:Mn nanoparticles at different excitation wavelengths. For comparison,
Rhodamine 6G is measured at 900 nm. S is the slope of the linear fitting. Between 900 and 1000 nm, the excitation mechanism is a three-photon
absorption, and between 1100 and 1180 nm, the excitation mechanism is switched to two-photon absorption. The efficiency of PL is highest when
excited at 1180 nm. Reprinted with permission from refs 42, 97, and 101. Copyright 2013 Macmillan Publishers Limited and 2013 American
Chemical Society.
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As described earlier, the multiphoton excitation of QDs using
NIR laser presents a number of advantages over UV excitation
of fluorescent dye, although light scattering from biological
tissues remains a problem that limits the fluorescence imaging
of deep tissues. To further minimize the light scattering, the
second near-infrared (NIR-II) range (1000 to 1700 nm) has
been suggested as a better optical window (Figure 4c).41,42 For
instance, ZnS:Mn QDs, which were previously described as a
three-photon imaging probe, were shown to have a superior
two-photon imaging characteristic under NIR-II excitation
(Figure 4d).101 Compared with the two-photon excitation of
ZnS host using a 600 nm laser, direct two-photon excitation of
the manganese dopants by a 1050−1310 nm light source can
benefit from the large two-photon absorption cross section of
the manganese ions and deeper light penetration depth of the
NIR-II window. However, the quantum efficiencies of QDs by
NIR or NIR-II multiphoton excitation are still very low. The
emission light from the QDs is also subjected to the absorption
and scattering by the tissues, which further reduces the imaging
quality. Finally, multiphoton imaging requires a microscope
equipped with an expensive high-power femtosecond pulsed
laser as an excitation source, and the laser beam should be
focused for scanning, which delays the data acquisition.
Therefore, the development of QDs with high multiphoton
quantum efficiency as well as the development of imaging
techniques for rapid acquisition of high-resolution images is
urgent for the wide application of multiphoton imaging.
■ LUMINESCENCE UPCONVERSION IMAGING
PROBES
Upconversion is another mechanism of the anti-Stokes
emission processes, and it has received much attention in
recent years to develop novel luminescent probes.93 Similar to
the multiphoton absorption, a NIR excitation source can be
used for deeper light penetration and minimal background
autofluorescence. Compared with the multiphoton absorption,
however, the upconversion mechanism involves the photon
absorption through real electronic intermediate states, resulting
in a much higher emission efficiency and a longer luminescence
lifetime up to several hundred microseconds.102,103 Therefore,
UCNPs can be excited at a low-power density using a
continuous-wave laser diode. As such, image scanning by the
focused pulsed laser is not necessary, and data acquisition can
be performed much faster using wide-field microscopy.104−107
Unlike the QDs, the emission wavelength of lanthanide-
doped inorganic UCNPs is not related to the quantum
confinement effect but dependent on the energy levels of
individual lanthanide elements.108,109 Therefore, emission color
tuning is achieved by controlling the elemental composition of
the UCNPs.110,111 Luminescence lifetime is also tunable from
several to thousands of microseconds by changing the type or
the percentage of dopants,103 which allows multiplex imaging
not only by different emission colors but also by different
lifetimes. The long luminescence lifetime of the UCNPs is also
beneficial to the time-gated fluorescence imaging, where
increased image contrast is obtained by separating the UCNP
emission from light scattering.112
Although the upconversion efficiency of the lanthanide-
doped inorganic UCNPs is exceeded by those of the organic
dye-based UCNPs that use triplet−triplet annihilation
upconversion,113,114 it has been shown that the photon
collection efficiency can be enhanced by functionalizing the
lanthanide-doped inorganic UCNPs with antenna materials
such as NIR dyes (Figure 5a),115−118 gold nanoshells,70 or
QDs.119 These antennas can also expand the range of
absorption wavelength, allowing the flexible choice of excitation
sources. In addition, more robust chemical stability and
photostability of the inorganic UCNPs than those of the
upconverting organic dyes in aqueous or air condition render
them better suited for bioimaging applications. Further efforts
to enhance the emission efficiency of the lanthanide-doped
inorganic UCNPs include the controlled doping of core−shell
structured UCNPs with different lanthanide dopants to
facilitate the energy transfer,102 and the high-irradiance
excitation of UCNPs, where the luminescence quenching of
the dopant ions is alleviated by the strong excitation power.120
While UCNPs are promising as a new luminescence imaging
probe, it is important to point out the current limitations of the
UCNPs. First of all, limited tunability of the emission
wavelength can restrict the multiplex imaging. Because of the
ladder-like energy levels of the lanthanide emitters, there are
always multiple emission peaks. For example, erbium ions
generate green and red emission, and thulium ions are known
to exhibit UV, blue, and NIR emission.121 Although there have
been several reports on obtaining pure emission colors from
UCNPs, especially for red, emission wavelength tuning is still a
challenging issue that requires further exploration.122,123
Another issue is the heating effect by 980 nm NIR laser,
which is usually used for the excitation of many types of
UCNPs. Since water molecules can absorb the photons of the
incident 980 nm laser, their temperature may increase. This
heating effect may not be noticeable in most cellular imaging
situations.104 However, the high-power laser used for in vivo
imaging may induce a thermal change large enough to affect the
upconversion luminescence properties of the UCNPs and
possibly cause damage to tissues. To minimize the heating
effect, alternative excitation wavelengths whose energies are less
absorbed by water molecules have been sought.124 In a recent
study, Nd3+ ions were introduced to UCNPs as a new sensitizer
dopant that can be excited at 800 nm with marginal heating
effect (Figure 5b).125−127 Further research on various
combinations of sensitizer and host materials is clearly needed
to develop an optimized system for clinical use.
UCNPs are not free from the biosafety issues. Since an
increasing number of UCNPs are now studied for in vivo
applications, careful evaluation of their potential toxic effects is
of great importance. To date, several systematic studies have
been made to investigate the in vivo toxicity of UCNPs in
mice,128−132 zebrafish embryos,133,134 and Caenorhabditis
elegans worms,135−137 and many results suggest little to no
toxicity with small doses (e.g., <1 mg/kg). UCNPs indeed can
be regarded as safer than the cadmium-containing QDs, but
they are not completely safe as an overdose of UCNPs still can
induce a severe toxicity. Consequently, the administration of
UCNPs for bioimaging should be kept as minimal as possible,
Since the nanoparticle probes are
usually composed of various in-
organic elements and organic
molecules for core material and
surface coating, respectively, in-
dividual components can be tail-
ored for specific applications.
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which again emphasizes the significance of developing efficient
probes.
■ CONCLUSION
Various inorganic nanoparticles have been developed and used
as probes for in vivo biomedical imaging. For MRI and CT,
several nanoparticle-based contrast agents have been shown to
outperform conventional small molecule-based contrast agents
in terms of imaging quality. Moreover, they are less toxic and
easier to functionalize with targeting or stimuli-responsive
ligands for effective treatment. The use of QDs or UCNPs for
optical imaging also works as a good alternative to the optical
imaging by organic dyes. The higher photostability and the
larger absorption cross section of the QDs and UCNPs endow
in vivo imaging with high-resolution and good signal-to-noise
ratio. Especially, imaging techniques based on the multiphoton
or upconversion process can make use of NIR light to obtain
the images of deeper tissues. Recently, photoacoustic imaging
has also emerged as a promising imaging technique to provide
centimeter penetration depth with micrometer resolution.138
Even though photoacoustic imaging exhibits better tissue
penetration capability than anti-Stokes shift-based lumines-
cence imaging, simultaneous imaging of multiple targets is only
allowed by luminescence multicolor imaging, which is an
advantage of luminescence-based imaging.111 Despite all these
benefits, nanoparticle imaging probes are not yet ready to
completely replace the conventional contrast agents or
fluorescence/luminescence dyes. Future research should be
aimed at improving the efficiencies of the imaging modalities as
well as the nanoparticle probes.
It is also worth mentioning the possibilities of the
nanoparticle probes for multifunctional capabilities. Since the
nanoparticle probes are usually composed of various inorganic
elements and organic molecules for core material and surface
coating, respectively, individual components can be tailored for
specific applications (Figure 5c).139 For example, Gd3+ ions
which exhibit T1 MRI contrast effects can be doped into
UCNPs to produce a luminescence/MRI dual-modal imaging
probe. And, Lu3+ (or Yb3+) ions of UCNPs which have high
atomic numbers can show a higher CT contrast enhancement
than iodinated ones. This kind of multimodal imaging strategy
is quite useful because the advantages of each imaging modality,
such as high sensitivity or high penetration depth, can be
combined altogether. Moreover, multimodal imaging probes
not only provide the means for complementary imaging of the
same region of interest but also can enable the imaging of
different regions by individual imaging techniques. As a result,
more comprehensive and reliable diagnosis is possible with
Figure 5. (a) Left: The schematic of multi-dye-sensitized UCNPs for a broad range of light absorption. Three dye sensitizers (e.g., BODIPY-FL for
blue absorption, Cy 3.5 for green absorption, and IR 806 for red absorption) are immobilized on the nanoparticles. Right: The energy diagram of the
three sensitizers and the UCNPs. (b) Left: The schematic of Nd3+-doped core/shell UCNPs excited under 800 nm irradiation. Right: The energy
diagram of the core/shell UCNPs. (c) NaLuF4:Yb,Tm@NaGdF4 (
153Sm) nanoparticles work as a multimodal imaging agent for upconversion
luminescence imaging (Yb3+,Tm3+), CT (Lu3+,Yb3+), T1 MRI (Gd
3+), and SPECT (153Sm3+). Reprinted with permission from refs 117, 125, and 139.
Copyright 2017 Wiley and 2013 American Chemical Society.
Moreover, multimodal imaging
probes not only provide the
means for complementary imag-
ing of the same region of interest
but also can enable the imaging
of different regions by individual
imaging techniques. As a result,
more comprehensive and reliable
diagnosis is possible with smaller
quantities of nanoparticle probes
than those for separate imaging.
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smaller quantities of nanoparticle probes than those for
separate imaging. Judicious design is necessary, though, as
simple integration without any specific purpose may not bring
any synergistic effect. In addition to the combination of
different imaging modalities, drug molecules can be incorpo-
rated onto the surface of the nanoparticle probes using
bioconjugation chemistry, producing theranostic agents.
There are still plenty of untapped possibilities for such
combinations that remain to be realized.
As always, biosafety of inorganic nanoparticle probes is
critical, and it should be assessed carefully to fully draw out the
potentials of the nanoparticle probes in bioimaging. While
several issues regarding the toxicity, biodistribution, and
clearance of nanoparticles in living animals have been
investigated for the past decade, our current understanding is
still far from complete. A bottom line would be synthesizing
nanoparticle probes using less toxic elements and green
chemistry if possible. Surface functionality and the overall size
of the nanoparticle probes, which are closely related to the
physical properties of the nanoparticle probes, are also known
to affect the circulation, uptake, distribution, and clearance
properties in vivo. Therefore, it would be required to optimize
various factors for the best in vivo results, since the nanoparticle
probes with the highest physical performance do not always
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(92) Gamelin, D. R.; Güdel, H. U. Design of Luminescent Inorganic
Materials: New Photophysical Processes Studied by Optical Spectros-
copy. Acc. Chem. Res. 2000, 33, 235−242.
(93) Auzel, F. Upconversion and Anti-Stokes Processes with F and D
Ions in Solids. Chem. Rev. 2004, 104, 139−173.
(94) Weissleder, R. A Clearer Vision for in vivo Imaging. Nat.
Biotechnol. 2001, 19, 316−317.
(95) Larson, D. R.; Zipfel, W. R.; Williams, R. M.; Clark, S. W.;
Bruchez, M. P.; Wise, F. W.; Webb, W. W. Water-Soluble Quantum
Dots for Multiphoton Fluorescence Imaging in vivo. Science 2003, 300,
1434−1436.
ACS Central Science Outlook
DOI: 10.1021/acscentsci.7b00574
ACS Cent. Sci. 2018, 4, 324−336
334
(96) Deng, Z. T.; Tong, L.; Flores, M.; Lin, S.; Cheng, J. X.; Yan, H.;
Liu, Y. High-Quality Manganese-Doped Zinc Sulfide Quantum Rods
with Tunable Dual-Color and Multiphoton Emissions. J. Am. Chem.
Soc. 2011, 133, 5389−5396.
(97) Yu, J. H.; Kwon, S.-H.; Petraśěk, Z.; Park, O. K.; Jun, S. W.;
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